title: Alefacept for psoriasis and psoriatic arthritis.
abstract: Alefacept is a bioengineered fusion protein of soluble lymphocyte function antigen (LFA-3) with Fc fragments of IgG1. It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis.
authors.affiliation: Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, 51 French St., New Brunswick, NJ 08901-0019, USA. alice.gottlieb@umdnj.edu
authors.forename: A B
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000077944:Alefacept; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D003131:Combined Modality Therapy; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept